Avsola

Avsola is a biologic medication used in the treatment of various autoimmune diseases. It is a biosimilar to infliximab, which is marketed under the brand name Remicade. Avsola is produced by Amgen, a leading biotechnology company.

Medical Uses

Avsola is primarily used to treat conditions such as:

• Rheumatoid arthritis
• Crohn's disease
• Ulcerative colitis
• Ankylosing spondylitis
• Psoriatic arthritis
• Plaque psoriasis

Mechanism of Action

Avsola works by inhibiting tumor necrosis factor alpha (TNFα), a pro-inflammatory cytokine. By blocking TNFα, Avsola helps to reduce inflammation and halt disease progression in autoimmune conditions.

Administration

Avsola is administered via intravenous infusion. The dosage and frequency of administration depend on the specific condition being treated and the patient's response to the therapy.

Side Effects

Common side effects of Avsola include:

• Infusion reactions
• Infections
• Headache
• Abdominal pain
• Nausea

Serious side effects may include:

• Severe infections
• Heart failure
• Liver toxicity
• Blood disorders

Regulatory Status

Avsola was approved by the U.S. Food and Drug Administration (FDA) in December 2019 as a biosimilar to Remicade. It is also approved in several other countries for the treatment of autoimmune diseases.

Related Pages

• Biologic medication
• Biosimilar
• Infliximab
• Remicade
• Amgen
• Autoimmune disease
• Tumor necrosis factor alpha